Skip to search formSkip to main contentSkip to account menu

gp100(17-25) peptide

Known as: ALLAVGATK, alanyl-leucyl-leucyl-alanyl-valyl-glycyl-alanyl-threonyl-lysine 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Peptidesgp100 Melanoma Antigen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.
The long-term survival of some patients with metastatic melanoma may be attributable in part to cellular immune responses to… 
1998
1998
Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients
A T cell line recognizing autologous and allogeneic HLA‐A3.1 melanomas was obtained from a disease‐free melanoma patient (patient… 
1997
1997
Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes.
The large majority of known melanoma-associated antigenic peptides presented by MHC class I molecules are presented by the most… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)